Biodesix (BDSX) Change in Accured Expenses (2019 - 2026)

Biodesix (BDSX) has reported Change in Accured Expenses for 8 consecutive years, with -$2.3 million the latest figure, recorded in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$2.3 million, down 20.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (up 55.73% YoY), and the FY2025 annual result was $1.9 million, up 13.56% from the prior year.
• Change in Accured Expenses was -$2.3 million for Q1 2026 at Biodesix, down from $974000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $3.3 million in Q2 2023 and troughed at -$2.3 million in Q1 2026.
• Average Change in Accured Expenses over 5 years is $52470.6, with a median of $486000.0 recorded in 2025.
• The widest YoY moves for Change in Accured Expenses: up 2897.25% in 2023, down 370.13% in 2023.
• Over 5 years, Change in Accured Expenses stood at -$127000.0 in 2022, then jumped by 698.43% to $760000.0 in 2023, then jumped by 122.89% to $1.7 million in 2024, then plunged by 42.5% to $974000.0 in 2025, then tumbled by 340.66% to -$2.3 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$2.3 million in Q1 2026, $974000.0 in Q4 2025, and $486000.0 in Q3 2025.